Active Not Recruiting PHASE2 INTERVENTIONAL 1-arm NCT06106295

Metyrapone for Mild Autonomous Cortisol Secretion (MACS)

Metyrapone Intervention in Patients With Mild Autonomous Cortisol Secretion (MACS)

Sponsor: Mayo Clinic

Conditions Autonomous Cortisol Secretion Mild Autonomous Cortisol Secretion (MACS)

Interventions Metyrapone

Updated 8 times since 2023 Last updated: Sep 16, 2025 Started: Dec 19, 2023 Primary completion: Jan 31, 2028 Completion: Feb 1, 2028

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06106295, this PHASE2 trial focuses on Autonomous Cortisol Secretion and Mild Autonomous Cortisol Secretion (MACS) and remains ongoing. Sponsored by Mayo Clinic, it has been updated 8 times since 2023, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

8 versions recorded

Oct 2025 — Present [monthly]

Active Not Recruiting PHASE2
Aug 2025 — Oct 2025 [monthly]

Active Not Recruiting PHASE2

Status: Recruiting → Active Not Recruiting
Sep 2024 — Aug 2025 [monthly]

Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE2
Feb 2024 — Jul 2024 [monthly]

Recruiting PHASE2

▶ Show 3 earlier versions

Jan 2024 — Feb 2024 [monthly]

Recruiting PHASE2
Dec 2023 — Jan 2024 [monthly]

Recruiting PHASE2
Nov 2023 — Dec 2023 [monthly]

Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Mayo Clinic

Data source: Mayo Clinic

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Rochester, United States